Drugs / contezolid acefosamil
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03747497 | Nov 2018 → Mar 2019 | gram-positive bacterial infections, skin disease caused by bacterial infection | MicuRx | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT05369052 | May 2022 → Jun 2026 overdue | — | MicuRx | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-09-21 | MicuRx | Regulatory 盟科药业：康替唑胺片和MRX-4获得美国FDA的合格传染病产品和快速通道资格认定 micurx.com ↗
近日，盟科药业宣布美国FDA授予康替唑胺片和MRX-4（contezolid acefosamil）用于治疗中度至重度糖尿病足感染且不伴有骨髓炎适应症合格传染病产品（QIDP）和快速通道（Fast Track）资格认定。 |
| 2019-09-09 | MicuRx | Results 盟科医药宣布新型抗生素康泰唑胺磷酸盐（ Contezolid Acefosamil）在美国开展的针对 ABSSSI的二期临床试验获得积极结果 micurx.com ↗
康泰唑胺磷酸盐达到了所有首要和次要的疗效终点，并显示了更好的血液学安全性。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-09-21 | MicuRx | 盟科药业：康替唑胺片和MRX-4获得美国FDA的合格传染病产品和快速通道资格认定 micurx.com ↗ |
| 2019-09-09 | MicuRx | 盟科医药宣布新型抗生素康泰唑胺磷酸盐（ Contezolid Acefosamil）在美国开展的针对 ABSSSI的二期临床试验获得积极结果 micurx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | contezolid acefosamil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03747497 ↗ |
| Route | Intravenous | “IV and oral contezolid acefosamil given twice a day for 10 to 14 days” NCT03747497 ↗ |
| Route | Oral | “IV and oral contezolid acefosamil given twice a day for 10 to 14 days” NCT03747497 ↗ |